Epigenetic Activation of TUSC3 Sensitizes Glioblastoma to Temozolomide Independent of MGMT Promoter Methylation Status

Temozolomide (TMZ) is an important first-line treatment for glioblastoma (GBM), but there are limitations to TMZ response in terms of durability and dependence on the promoter methylation status of the DNA repair gene O(6)-methylguanine DNA methyltransferase (MGMT). MGMT-promoter-hypermethylated (MG...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Qiong, Berglund, Anders E., Macaulay, Robert J., Etame, Arnold B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10606804/
https://www.ncbi.nlm.nih.gov/pubmed/37894860
http://dx.doi.org/10.3390/ijms242015179

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10606804/
https://www.ncbi.nlm.nih.gov/pubmed/37894860
http://dx.doi.org/10.3390/ijms242015179

Ejemplares similares